Iovance Biotherapeutics, Inc. (FRA:2LB)
Germany
· Delayed Price · Currency is EUR 1.891
+0.035 (1.91%)
Last updated: Dec 4, 2025, 8:07 AM CET
Iovance Biotherapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Cash & Equivalents | 158.13 | 115.69 | 114.89 | 231.73 | 78.23 | 67.33 | Upgrade
|
| Short-Term Investments | 142.67 | 208.09 | 164.98 | 240.11 | 426.18 | 562.11 | Upgrade
|
| Cash & Short-Term Investments | 300.8 | 323.78 | 279.87 | 471.85 | 504.41 | 629.44 | Upgrade
|
| Cash Growth | -24.32% | 15.69% | -40.69% | -6.46% | -19.86% | 104.97% | Upgrade
|
| Receivables | 66.76 | 69.34 | 0.15 | - | - | - | Upgrade
|
| Inventory | 51.71 | 51.52 | 10.37 | - | - | - | Upgrade
|
| Prepaid Expenses | 9.82 | 12.38 | 17.46 | 7.27 | 3.55 | 6.66 | Upgrade
|
| Total Current Assets | 429.09 | 457.02 | 307.85 | 479.12 | 507.96 | 636.1 | Upgrade
|
| Property, Plant & Equipment | 175.41 | 164.28 | 176.55 | 178.25 | 169.92 | 113.92 | Upgrade
|
| Long-Term Investments | - | - | - | - | 91.59 | - | Upgrade
|
| Other Intangible Assets | 285.21 | 282.4 | 229.26 | - | - | - | Upgrade
|
| Other Long-Term Assets | 15.24 | 6.73 | 66.7 | 6.62 | 7.87 | 18.44 | Upgrade
|
| Total Assets | 904.95 | 910.43 | 780.35 | 663.98 | 777.33 | 768.46 | Upgrade
|
| Accounts Payable | 31.24 | 27.51 | 33.12 | 26.6 | 27.38 | 13.51 | Upgrade
|
| Accrued Expenses | 82.91 | 75.19 | 66.97 | 45.79 | 51.91 | 30.73 | Upgrade
|
| Current Portion of Leases | 6.28 | 12.9 | 7.78 | 12.59 | 5.06 | 6.28 | Upgrade
|
| Other Current Liabilities | 4.36 | 6.75 | 2.44 | 6.51 | 4.86 | 4.34 | Upgrade
|
| Total Current Liabilities | 125.79 | 122.34 | 110.31 | 91.49 | 89.2 | 54.87 | Upgrade
|
| Long-Term Debt | - | 1 | 1 | 1 | 1 | - | Upgrade
|
| Long-Term Leases | 45.21 | 44.37 | 67.09 | 71.86 | 65.47 | 45.38 | Upgrade
|
| Long-Term Deferred Tax Liabilities | 31.67 | 32.32 | 17.35 | - | - | - | Upgrade
|
| Other Long-Term Liabilities | - | - | - | - | - | 11.71 | Upgrade
|
| Total Liabilities | 202.66 | 200.02 | 195.74 | 164.34 | 155.67 | 111.96 | Upgrade
|
| Common Stock | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | Upgrade
|
| Additional Paid-In Capital | 3,390 | 3,096 | 2,594 | 2,069 | 1,795 | 1,487 | Upgrade
|
| Retained Earnings | -2,704 | -2,385 | -2,012 | -1,568 | -1,172 | -830.19 | Upgrade
|
| Comprehensive Income & Other | 16.1 | -1.05 | 2.53 | -0.9 | -0.6 | 0.02 | Upgrade
|
| Total Common Equity | 702.29 | 710.4 | 584.61 | 499.64 | 621.66 | 656.49 | Upgrade
|
| Shareholders' Equity | 702.29 | 710.41 | 584.61 | 499.64 | 621.66 | 656.5 | Upgrade
|
| Total Liabilities & Equity | 904.95 | 910.43 | 780.35 | 663.98 | 777.33 | 768.46 | Upgrade
|
| Total Debt | 52.49 | 58.26 | 75.86 | 85.45 | 71.53 | 51.66 | Upgrade
|
| Net Cash (Debt) | 248.31 | 265.52 | 204.01 | 386.4 | 432.88 | 577.78 | Upgrade
|
| Net Cash Growth | -22.05% | 30.15% | -47.20% | -10.74% | -25.08% | 95.47% | Upgrade
|
| Net Cash Per Share | 0.75 | 0.92 | 0.87 | 2.43 | 2.82 | 4.18 | Upgrade
|
| Filing Date Shares Outstanding | 396.97 | 327.88 | 279.31 | 224.24 | 157.17 | 146.98 | Upgrade
|
| Total Common Shares Outstanding | 385.46 | 305.25 | 256.14 | 187.81 | 157 | 146.87 | Upgrade
|
| Working Capital | 303.31 | 334.68 | 197.54 | 387.63 | 418.76 | 581.23 | Upgrade
|
| Book Value Per Share | 1.82 | 2.33 | 2.28 | 2.66 | 3.96 | 4.47 | Upgrade
|
| Tangible Book Value | 417.08 | 428 | 355.35 | 499.64 | 621.66 | 656.49 | Upgrade
|
| Tangible Book Value Per Share | 1.08 | 1.40 | 1.39 | 2.66 | 3.96 | 4.47 | Upgrade
|
| Machinery | 40.24 | 34.28 | 33.27 | 31.79 | 14.87 | 5.41 | Upgrade
|
| Construction In Progress | 32.83 | 34.94 | 24.1 | 9.12 | 35.78 | 56.76 | Upgrade
|
| Leasehold Improvements | 90.4 | 67.38 | 76.8 | 74.31 | 57.82 | 2.57 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.